• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Autonomix Medical Inc.

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care
    Get the next $AMIX alert in real time by email
    SC 13G 1 tm2429659d1_sc13g.htm SC 13G

     

     

     

    CUSIP No:   05330T205

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____)*

     

    Autonomix Medical, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    05330T205
    (CUSIP Number)

     

    November 22, 2024

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨  Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No:   05330T205

     

      (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    193,972
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    193,972

     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        193,972
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
        ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        9.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:   05330T205

     

      (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    193,972
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    193,972

     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        193,972
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        9.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:   05330T205

     

    Item 1.

     

    (a)    Name of Issuer

     

    Autonomix Medical, Inc. (the “Company”)

     

    (b)    Address of Issuer’s Principal Executive Offices

     

    21 Waterway Avenue, Suite 300, The Woodlands, TX 77380

     

    Item 2(a).     Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).     Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).     Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)     Title of Class of Securities

     

    Common stock, $0.001 par value per share

     

    Item 2(e)      CUSIP Number

     

    05330T205

     

     

     

     

    CUSIP No:   05330T205

     

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)  ¨    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)  ¨     Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)  ¨     Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)  ¨     Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)  ¨     An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)  ¨      An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)  ¨     A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)  ¨     A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)  ¨      A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)  ¨      A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)  ¨     Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.    Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of (i) 135,000 Shares, and (ii) Shares issuable upon the exercise of pre-funded warrants to purchase Shares (the “Pre-Funded Warrants”). The Pre-Funded Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 9.99%.

     

    The Company’s Prospectus (Registration No. 333-282940), filed on November 25, 2024, indicates there were 1,882,686 Shares outstanding (excluding Shares underlying the Pre-Funded Warrants and certain other warrants issued at the same time) as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No:   05330T205

     

    Item 5.    Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.    Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.    Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.    Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.  Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No:   05330T205

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: November 27, 2024

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney, a copy of which is attached   Name: Brian Sopinsky
    as Exhibit I hereto   Title: Secretary
         
    By: /s/ Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary    
             

     

     

     

     

    CUSIP No:   05330T205

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement

     

     

      

    Get the next $AMIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Robins David Andrew

      4 - Autonomix Medical, Inc. (0001617867) (Issuer)

      7/26/24 4:06:58 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Bisson Lori

      4 - Autonomix Medical, Inc. (0001617867) (Issuer)

      6/24/24 5:10:04 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Klemp Walter V

      4 - Autonomix Medical, Inc. (0001617867) (Issuer)

      6/24/24 5:09:31 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care

    $AMIX
    SEC Filings

    See more
    • Autonomix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Autonomix Medical, Inc. (0001617867) (Filer)

      4/30/25 8:15:11 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Autonomix Medical Inc.

      EFFECT - Autonomix Medical, Inc. (0001617867) (Filer)

      3/12/25 12:15:04 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form S-3/A filed by Autonomix Medical Inc.

      S-3/A - Autonomix Medical, Inc. (0001617867) (Filer)

      3/7/25 5:28:29 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care

    $AMIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

      Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here THE WOODLANDS, TX, May 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of a new video testimonial from a patient participating in the initial phase of its first-in-human proof-of-concept trial ("PoC 1") evaluating the safety and effectiveness of delivering transv

      5/5/25 8:30:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

      Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase ("POC 1") where clinically meaningful pain reduction was demonstrated Outlines Company's plans to initiate market expansion study ("POC 2") into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the "What This Means" video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently pa

      5/1/25 9:25:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

      Initial trial phase ("PoC 1") achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up Company has initiated market expansion study ("PoC 2") of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025 Additional indications potentially double the addressable market beyond pancreatic cancer pain THE WOODLANDS, TX, April 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies

      4/30/25 8:15:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care

    $AMIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

      Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th

      12/19/24 8:30:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

      Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman

      6/17/24 4:05:00 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Appoints Jennifer Cook as Chief Business Officer

      Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c

      3/19/24 8:45:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care

    $AMIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Autonomix Medical Inc.

      SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

      12/3/24 6:17:58 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Autonomix Medical Inc.

      SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

      11/27/24 10:15:18 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Autonomix Medical Inc.

      SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

      10/7/24 8:30:24 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care